Fresh2 Group (Fresh2 Group) Cash, Cash Equivalents, Marketable Securities : $0.07 Mil (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Fresh2 Group Cash, Cash Equivalents, Marketable Securities?

Fresh2 Group's quarterly cash, cash equivalents, marketable securities declined from Sep. 2022 ($1.08 Mil) to Dec. 2022 ($0.27 Mil) but then stayed the same from Dec. 2022 ($0.27 Mil) to Jun. 2023 ($0.07 Mil).

Fresh2 Group's annual cash, cash equivalents, marketable securities increased from Dec. 2020 ($0.46 Mil) to Dec. 2021 ($1.45 Mil) but then declined from Dec. 2021 ($1.45 Mil) to Dec. 2022 ($0.27 Mil).

Fresh2 Group Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Fresh2 Group's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresh2 Group Cash, Cash Equivalents, Marketable Securities Chart

Fresh2 Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

1.87

0.87

0.46

1.45

0.27

Fresh2 Group Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial														0.07	1.03	1.08	0.27	0.07

Fresh2 Group Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Fresh2 Group (NAS:FRES) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Fresh2 Group Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Fresh2 Group's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Fresh2 Group (Fresh2 Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh2 Group Ltd (NAS:FRES) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

0UC0:Germany

Address

650 5TH Avenue, Street 2416, NEW YORK, NY, USA, 10019-6108

Website

https://www.fresh2.co

Fresh2 Group Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated the potential to assist physicians in cancer diagnosis, prognosis, and recurrence.